Latest News on CRAI

Financial News Based On Company


Advertisement
Advertisement

Form 4 CRA International Inc: Paul A. Maleh (Director, PRESIDENT AND CEO) For: 17 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-cra-international-inc-paul-a-maleh-director-president-and-ceo-for-17-november-93CH-5716705
This article reports on a Form 4 filing for CRA International Inc, detailing an insider transaction by Paul A. Maleh, who serves as a Director, President, and CEO. The transaction date specified in the filing is November 17. The article itself does not provide specific details about the nature of the transaction.

Cra international CEO Paul Maleh sells $1.54 million in company stock By Investing.com

https://in.investing.com/news/stock-market-news/cra-international-ceo-paul-maleh-sells-154-million-in-company-stock-93CH-5716699
Paul A. Maleh, CEO of CRA International, Inc., sold 7,500 shares of company stock for approximately $1.54 million on November 17, 2026, through a pre-arranged trading plan. Despite this sale, the company recently reported strong third-quarter 2026 results, exceeding expectations with record earnings and revenue, and increased its full-year revenue guidance. CRA International also approved a 17.5% dividend increase, marking its tenth consecutive annual raise, reflecting robust demand across its consulting practices.

Form 4 CRA International Inc: Paul A. Maleh (Director, PRESIDENT AND CEO) For: 17 November

https://ca.investing.com/news/stock-market-news/form-4-cra-international-inc-paul-a-maleh-director-president-and-ceo-for-17-november-93CH-4971252
This article reports on a Form 4 filing for CRA International Inc, detailing that Paul A. Maleh, who serves as Director, President, and CEO, was involved in a transaction on November 17. The filing provides public notice of changes in the ownership of company stock by an insider. The specific details of the transaction are not provided in this brief announcement.

Form 144 CRA INTERNATIONAL For: 18 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-cra-international-for-18-november-93CH-4965882
This article from Investing.com announces the filing of Form 144 for CRA International (CRAI) on November 18, 2026. Form 144 indicates an intent to sell restricted or control securities. The brief notice highlights the company's stock performance (-0.61%) and includes standard disclaimers about market data and trading risks.

Form 4 CRA International Inc: Brian Langan (Officer) For: 14 September

https://uk.investing.com/news/stock-market-news/form-4-cra-international-inc-brian-langan-officer-for-14-september-93CH-4983053
This article reports on a Form 4 filing for CRA International Inc, indicating an insider transaction involving Officer Brian Langan. The filing date mentioned is September 14. The article provides no further details on the nature of the transaction.
Advertisement

Form 4 CRA International Inc: Brian Langan (Officer) For: 14 September

https://ca.investing.com/news/stock-market-news/form-4-cra-international-inc-brian-langan-officer-for-14-september-93CH-4959034
This article reports on a Form 4 filing for CRA International Inc, detailing an insider transaction involving officer Brian Langan. The filing is related to activity on September 14. The information is provided by Investing.com, a financial markets news source.

Form 4 CRA International Inc: Chad M. Holmes (EVP AND CHIEF CORP DEV OFFICER) For: 14 September

https://ca.investing.com/news/stock-market-news/form-4-cra-international-inc-chad-m-holmes-evp-and-chief-corp-dev-officer-for-14-september-93CH-4959025
This article reports a Form 4 filing for CRA International Inc, detailing an insider transaction involving Chad M. Holmes, EVP and Chief Corporate Development Officer, on September 14. The filing provides transparency on changes in ownership for key executives.

Form 4 CRA International Inc: Chad M. Holmes (EVP AND CHIEF CORP DEV OFFICER) For: 14 September

https://in.investing.com/news/stock-market-news/form-4-cra-international-inc-chad-m-holmes-evp-and-chief-corp-dev-officer-for-14-september-93CH-5705121
This article reports on a Form 4 filing for CRA International Inc., specifically mentioning Chad M. Holmes, EVP AND CHIEF CORP DEV OFFICER. The filing pertains to activity on September 14th. The article provides the headline without further details regarding the transaction itself.

How Investors May Respond To CRA International Stock After Dividend Hike

https://simplywall.st/stocks/us/commercial-services/nasdaq-crai/cra-international/news/how-investors-may-respond-to-cra-international-stock-after-d
CRA International, Inc. reported strong Q3 2026 sales and net income, leading its Board to approve a quarterly dividend increase from US$0.57 to US$0.67 per share. This move signals management's confidence in the company's consulting demand and cash generation, while also raising expectations for sustained advisory activity and efficient capital management to cover increased payouts and debt service. The article also provides analyst forecasts and fair value estimates, suggesting potential upside for the stock.

CRA International, Inc. (CRAI) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/CRAI/
CRA International, Inc. (CRAI) stock closed at $205.32, up 3.04%, and announced a cash dividend of $0.67 with an ex-date of November 24, 2026. The company, a global provider of economic, financial, and management consulting services, has shown strong performance with a 1-year return of 14.73% and a 3-year return of 131.92%, outperforming the S&P 500. Analysts currently have an average price target of $250.50 for CRAI.
Advertisement

CRA International (NASDAQ:CRAI) Raises Dividend Tenth Year

https://kalkinemedia.com/us/stocks/dividend/cra-international-nasdaqcrai-raises-dividend-tenth-year
CRA International, Inc. (NASDAQ:CRAI) announced a significant increase in its quarterly cash dividend, marking its tenth consecutive annual raise since its inaugural dividend. This move, coinciding with its third-quarter 2026 results, signals management's strong confidence in sustained healthy cash flow from its economic, financial, and management consulting services. The firm specializes in litigation support and antitrust analysis, areas known for stable demand even during broader economic shifts, which underpins its ability to consistently return capital to shareholders.

CRA International, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CRAI) 2026-11-09

https://seekingalpha.com/article/4965436-cra-international-inc-2026-q3-results-earnings-call-presentation
CRA International, Inc. (CRAI) published its slide deck in conjunction with its 2026 Q3 earnings call, where it reported an EPS of $2.19, beating estimates by $0.12. The company also announced revenue of $214.92 million, a 15.61% year-over-year increase, surpassing expectations by $15.88 million.

CRA International, Inc. (CRAI) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/CRAI/
This article provides a comprehensive overview of CRA International, Inc. (CRAI) stock, including its current price, dividend information, key financial statistics, and performance compared to the S&P 500. It also details the company's consulting services, analyst insights, and earnings trends, along with a brief profile of the company.

CRA International Sets Fiscal 2026 Revenue Outlook at $830 Million to $840 Million

https://www.tokenpost.com/news/business/50579
CRA International, Inc. (CRAI) has projected fiscal 2026 revenue to be between $830 million and $840 million, alongside a non-GAAP EBITDA margin forecast of 12.2% to 12.8%. This outlook follows a strong third quarter where revenue surged by 15.6% year-over-year to $214.9 million, setting a new quarterly financial record for the company.

CRA International Inc (CRAI) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...

https://sg.finance.yahoo.com/news/cra-international-inc-crai-q3-070946674.html
CRA International Inc (CRAI) announced record quarterly revenue of $214.9 million, a 15.6% year-over-year increase, and raised its full-year revenue guidance to $830-$840 million. The company also increased its quarterly dividend by 17.5% to $0.67 per share, marking its tenth consecutive annual increase. Despite positive growth, concerns remain regarding a sequential decrease in global M&A activity, an elevated effective tax rate, and an increase in days sales outstanding.
Advertisement

Revenue rises 15.6% at CRA International (CRAI), but year-to-date profit falls.

https://www.stocktitan.net/sec-filings/CRAI/10-q-cra-international-inc-quarterly-earnings-report-adc8ddb9e826.html
CRA International (CRAI) reported a 15.6% increase in fiscal third-quarter revenue to $214.9 million, with net income rising to $13.9 million. However, fiscal year-to-date revenue, while up 13.0% to $626.7 million, saw net income fall by $3.1 million to $38.5 million, and operating activities used $43.9 million in cash. The company also declared a quarterly cash dividend of $0.67 per share.

Profit rises 21.2% at CRA International (CRAI) as quarterly revenue climbs.

https://www.stocktitan.net/sec-filings/CRAI/8-k-cra-international-inc-reports-material-event-b2da3d59c4a7.html
CRA International (CRAI) reported a strong fiscal third quarter for 2026, with revenue increasing 15.6% year-over-year to $214.9 million and net income rising 21.2% to $13.9 million. Diluted earnings per share grew by 27.2% to $2.20. The company also increased its full-year fiscal 2026 revenue guidance and raised its quarterly cash dividend by 17.5% to $0.67 per common share.

CRAI: CRA International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/cra-international-inc-filed-sec-form-8-k-results-of-operations-6774940
CRA International (CRAI) reported strong fiscal third-quarter results, with revenue up 15.6% year-over-year to $214.9 million and diluted EPS of $2.20. The company raised its full-year revenue guidance to $830 million-$840 million and increased its quarterly dividend by 17.5% to $0.67 per share. While net income and EPS reached historical highs for a third quarter, non-GAAP net income margin slightly decreased.

Charles River Associates (CRA) Increases Quarterly Cash Dividend 17.5% to $0.67 Per Common Share

https://www.stocktitan.net/news/CRAI/charles-river-associates-cra-increases-quarterly-cash-dividend-17-5-j5dw28qwc5cl.html
Charles River Associates (NASDAQ: CRAI) announced a 17.5% increase in its quarterly cash dividend, raising it from $0.57 to $0.67 per common share. This dividend will be paid on December 11, 2026, to shareholders of record as of November 24, 2026. The company, a global leader in economic, financial, and management consulting, expects to continue paying quarterly dividends at the discretion of its Board of Directors.

CRA International (CRAI) Stock Forecast & Analyst Ratings

https://www.moomoo.com/stock/CRAI-US/forecast?chain_id=Name1K9-3FXPhg.1l9c5c0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2F74611659%2Fpost%2Fall%22%7D
This article provides a detailed stock forecast for CRA International (CRAI), including average analyst price targets, a range of analyst opinions, and a summary of recent analyst actions. It also includes key financial metrics and a brief overview of the company's business.
Advertisement

CRA International, Inc. (CRAI) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CRAI/seasonality/
This article provides a seasonal returns chart for CRA International, Inc. (CRAI), showing average monthly price returns from 2016 to 2026. It includes current stock data and links to various financial metrics for the company on Yahoo Finance.

Barrington Maintains CRA International(CRAI.US) With Buy Rating, Maintains Target Price $245

https://www.moomoo.com/news/post/1002657083/barrington-maintains-cra-international-craius-with-buy-rating-maintains-target
Barrington has reiterated its Buy rating for CRA International (CRAI.US), an economic, financial, and management consulting services firm. The firm also maintained its target price of $245 for CRAI, signaling continued confidence in the company's stock performance.

CRA International, Inc. (CRAI)

https://milkroad.com/assets/crai/
CRA International, Inc. (CRAI) is trading at $192.84 USD with a market cap of $1.22 billion. The company has a P/E ratio of 24.7x and a forward P/E of 20.3x, with annual revenue of $795 million, showing a 12.8% year-over-year growth. Key institutional holders include Renaissance Technologies and Citadel Advisors, who have recently adjusted their holdings.

CRA International schedules November 5 results: USD 805 million guides CRA International stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-schedules-november-5-results-usd-805-million-guides-cra-international-stock/70406661
CRA International (CRAI) is scheduled to report its third-quarter 2026 financial results on November 5, 2026, at 10:00 a.m. ET. The company previously raised its full-year 2026 revenue guidance to between USD 805 million and USD 820 million, following a strong second quarter where revenue hit USD 210.81 million, marking a 12.80 percent year-over-year increase. Investors will focus on whether the company meets its revenue guidance and reaffirms its non-GAAP EBITDA margin outlook.

CRA International,Inc. Estimates – NASDAQ:CRAI

https://www.tradingview.com/symbols/NASDAQ-CRAI/financials-estimates/
This article provides an overview of CRA International, Inc. (NASDAQ: CRAI) financials and analyst estimates on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The page emphasizes that the information is not investment advice and encourages users to conduct their own research.
Advertisement

CRA International | 4: Statement of changes in beneficial ownership of securities-Officer Yellin Jonathan D

https://www.moomoo.com/news/notice/308146819/statement-of-changes-in-beneficial-ownership-of-securities-officer-yellin
This article indicates that there has been a statement of changes in beneficial ownership of securities for Officer Jonathan D. Yellin at CRA International. The content is presented as a "Document," suggesting a formal filing or report detailing these changes.

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5

https://finance.yahoo.com/markets/stocks/articles/charles-river-associates-cra-host-123000542.html
Charles River Associates (NASDAQ: CRAI) announced it will host a conference call on Thursday, November 5, 2026, at 10:00 a.m. ET to discuss its third-quarter fiscal 2026 financial results. The call will be webcast live on CRA's investor relations website and will feature President and CEO Paul Maleh, CFO Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes. Prior to the call, CRA will release its financial results and supplemental information on its website.

Charles River Associates (CRA) to Host Third-Quarter Fiscal 2026 Financial Results Conference Call on November 5

https://www.financialcontent.com/article/bizwire-2026-10-22-charles-river-associates-cra-to-host-third-quarter-fiscal-2026-financial-results-conference-call-on-november-5
Charles River Associates (CRA) announced it will webcast its third-quarter 2026 financial results conference call on Thursday, November 5, 2026, at 10:00 a.m. ET. The call will feature President and CEO Paul Maleh, CFO Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes. Investors can access the live webcast or dial in via telephone, with supplemental financial information posted on CRA's Investor Relations section prior to the call.

Barrington target leaves CRA International stock 26.39 percent below it

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barrington-target-leaves-cra-international-stock-26-39-percent-below-it/70377501
CRA International's stock is trading 26.39 percent below Barrington Research's target of USD 245.00, despite the company reporting an improved operating margin of 11.17 percent and a 12.80 percent revenue increase in fiscal second-quarter 2026. Analyst Kevin Steinke maintained a Buy rating on the stock, which last traded at USD 180.35 on Nasdaq, while the company's market capitalization stands at USD 1.1 billion.

CRA International stock was last at USD 178.09 on October 16, 2026 at 23.71 times earnings

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-stock-was-last-at-usd-178-09-on-october-16-2026-at-23-71-times-earnings/70348791
CRA International's stock closed at USD 178.09 on October 16, 2026, marking a 0.42 percent increase on Nasdaq and a price-to-earnings ratio of 23.71. The company reported strong second-quarter revenue of USD 210.81 million, exceeding analyst estimates. Despite a lower market capitalization and P/E ratio compared to some peers, analysts maintained a "Buy" rating for CRA International.
Advertisement

CRA International stock was last at USD 178.09 on October 16, 2026 at 23.71 times earnings

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-stock-was-last-at-usd-178-09-on-october-16-2026-at/70348791
CRA International's stock was last traded at USD 178.09 on October 16, 2026, marking a 0.42 percent increase on Nasdaq, with a price-to-earnings ratio of 23.71. The company reported second-quarter revenue of USD 210.81 million, surpassing estimates, and a market capitalization of USD 1.1 billion. The stock's performance and valuation are compared to industry peers Huron Consulting Group and Exponent.

Barrington keeps USD 245.00 target for CRA International stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barrington-keeps-usd-245-00-target-for-cra-international-stock/70333035
Barrington analyst Kevin Steinke maintained a Buy rating and a $245.00 price target for CRA International (CRAI) stock on October 2, 2026. This target represents a 37.64 percent upside from the Nasdaq quote of $178.00 on October 15, 2026. The consulting firm reported a 12.80 percent increase in fiscal second-quarter revenue, reaching $210.81 million, and traded within a 52-week range of $132.17 to $227.29.

Weekly Recap: 50%+ cash-return plan and antitrust-focused revenue

https://www.tradingview.com/news/tradingview:b103ad283bc95:0-weekly-recap-50-cash-return-plan-and-antitrust-focused-revenue/
CRA International, Inc. (CRAI) plans to return at least 50% of its adjusted operating cash flow to shareholders, having already repurchased $184 million in shares over five years. The company is guiding for mid-single-digit headcount growth, with approximately 80% of its revenue derived from legal and regulatory services, and 45% specifically from antitrust work. This strategy highlights a focus on specialized consulting services and shareholder returns.

CRA International Q2FY26 Results: Revenue up 12.8% to record $210.8M

https://scanx.trade/stock-market-news/companies/cra-international-q2fy26-results-revenue-up-12-8-record-210-8m/53100801
CRA International reported record Q2FY26 revenue of $210.8 million, a 12.8% year-over-year increase, driven by strong demand in legal, regulatory, and management consulting, with international revenue surging 32.9%. The company also raised its full-year revenue guidance to $805-$820 million and returned $31.4 million to shareholders through dividends and buybacks, while expanding its credit facility to $400 million to support growth. Despite an anticipated increase in non-cash forgivable loan amortization due to new senior talent, operational efficiency improvements led to a 15.3% rise in non-GAAP EBITDA.

CRA Intl Q2 2026 Earnings Call: Complete Transcript

https://www.benzinga.com/news/26/10/62272006/cra-intl-q2-2026-earnings-call-complete-transcript
CRA Intl reported record Q2 2026 revenue of $210.8 million, a 12.8% year-over-year increase, driven by strong performance across eight practices and significant international growth. The company also achieved its highest Q2 profits, with non-GAAP net income, EPS, and EBITDA seeing substantial increases. Management raised its annual revenue guidance to $805-$820 million while reaffirming EBITDA margin guidance, citing a robust sales pipeline and favorable market conditions, and highlighted strategic investments in talent and an expanded credit facility to support future growth.
Advertisement

CRA adds Feng Zhu and CRA International stock costs EUR 156.50

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-adds-feng-zhu-and-cra-international-stock-costs-eur-156-50/70267000
CRA International has appointed Harvard Business School Professor Feng Zhu as an academic affiliate, enhancing its Antitrust & Competition Economics Practice with expertise in platform economics, analytics, and AI. The company's stock was trading at EUR 156.50 at Lang & Schwarz, and its Q2 revenue exceeded consensus. CRA has a market capitalization of USD 1.1 billion and its next earnings date is listed for October 29, 2026.

CRA International appoints Zealey: Barrington rates CRA International stock Buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-appoints-zealey-barrington-rates-cra-international-stock-buy/70249489
CRA International has appointed Christopher Zealey as a vice president in its Life Sciences Practice, expanding its commercial strategy expertise. This appointment follows a maintained "Buy" rating and a $245.00 price target from Barrington analyst Kevin Steinke. The company reported a 12.80% increase in fiscal second-quarter revenue to $210.80 million and raised its fiscal 2026 constant-currency revenue guidance.

CRA International appoints Zealey: Barrington rates CRA International stock Buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-appoints-zealey-barrington-rates-cra-international/70249489
CRA International appointed Christopher Zealey as VP in its Life Sciences Practice, following an earlier VP appointment, expanding its commercial strategy expertise. Barrington analyst Kevin Steinke maintained a Buy rating and set a USD 245.00 price target for CRA International, citing strong Q2 2026 revenue growth of 12.80% to USD 210.80 million and increased fiscal 2026 constant-currency revenue guidance. The company also reaffirmed its non-GAAP EBITDA margin guidance, indicating a robust financial outlook despite market tensions.

CRA International (NasdaqGS:CRAI) Stock Price

https://simplywall.st/stock/nasdaqgs/crai
CRA International (CRAI) stock is currently trading at US$176.73, which is 29.4% undervalued compared to its fair value of US$250.50. The company reported record Q2 2026 revenue of $210.8 million, a 12.8% year-on-year increase, and raised its full-year 2026 revenue guidance to between $805 and $820 million. Despite strong demand in several sectors and an upgraded revenue outlook, the stock has seen an 11.9% decline year-to-date, raising questions about execution risk.

A new adviser joins Charles River Associates to help plan medical strategy and drug launches

https://www.stocktitan.net/news/CRAI/charles-river-associates-cra-bolsters-life-sciences-practice-with-v0cbfa0prbq5.html
Charles River Associates (CRA) has announced the appointment of Christopher Zealey as a Vice President in its Life Sciences Practice. Zealey's expertise includes medical strategic planning, insight generation, scientific communication, and clinical positioning, which will strengthen CRA's capabilities in supporting clients with complex medical affairs and drug launch decisions. This addition aims to bolster CRA's offerings during a period of significant growth and opportunity within the life sciences sector.
Advertisement

CRA International stock faces a 43.0 percent analyst target gap

https://www.ad-hoc-news.de/boerse/news/corporate-news/cra-international-stock-faces-a-43-0-percent-analyst-target-gap/70241052
CRA International (CRAI) stock closed at USD 171.29, significantly below the consensus target of USD 245.00, representing a 43.0 percent gap. This target is based on limited analyst coverage with a "Moderate Buy" consensus. The company recently reported strong Q2 2026 revenue and increased its full-year guidance.

Charles River Associates (CRA) Bolsters Life Sciences Practice with Appointment of Christopher Zealey as Vice President

https://finance.yahoo.com/healthcare/articles/charles-river-associates-cra-bolsters-123000190.html
Charles River Associates (CRA) has announced the appointment of Christopher Zealey as Vice President in its Life Sciences Practice. Zealey's expertise in medical and strategic planning, insight generation, and clinical positioning will further strengthen CRA's capabilities in supporting life sciences clients with complex challenges. This appointment comes as CRA expands its services in medical affairs strategy, leveraging data and stakeholder perspectives to deliver integrated solutions.

CRA International stock adds life sciences leadership with Hillan appointment

https://www.ad-hoc-news.de/boerse/news/corporate-news/cra-international-stock-adds-life-sciences-leadership-with-hillan-appointment/70237148
CRA International has appointed Patrick Hillan as Vice President for Life Sciences Commercial Strategy, expanding its leadership in a key sector. This appointment follows a strong Q2 revenue beat, with the company reporting USD 210.81 million against an expected USD 198.91 million. Analysts maintain a "Moderate Buy" rating with a target price significantly above the current stock value, highlighting both recent performance and strategic growth in life sciences.

Charles River Associates Sees AI, Energy and Cybersecurity Fueling Growth

https://finance.yahoo.com/technology/ai/articles/charles-river-associates-sees-ai-120205084.html
Charles River Associates (CRAI) anticipates continued growth fueled by demand in AI, energy, and cybersecurity sectors, according to CEO Paul Maleh. The company reported 12% revenue growth in the first half of 2026 and aims to return at least 50% of adjusted operating cash flow to shareholders through buybacks and dividends. AI is seen as both a demand amplifier and productivity enhancer, contributing to growth in areas like data center energy planning, pharmaceutical commercialization, and cyber incident response.

A Harvard professor who advises leaders at Meta and Uber joins Charles River Associates

https://www.stocktitan.net/news/CRAI/charles-river-associates-cra-adds-harvard-business-school-professor-rai96z3i5xs5.html
Charles River Associates (NASDAQ: CRAI) has appointed Professor Feng Zhu of Harvard Business School as an Academic Affiliate within its Antitrust & Competition Economics Practice. Professor Zhu is recognized for his expertise in digital transformation, competitive strategy, and business model innovation, having advised major tech companies like Alphabet, Meta, Microsoft, and Uber. His work will help CRA clients navigate complex issues related to digital markets and antitrust matters, including those specific to China.
Advertisement

Earnings Beat Might Change The Case For Investing In CRA International Stock (CRAI)

https://simplywall.st/stocks/us/commercial-services/nasdaq-crai/cra-international/news/earnings-beat-might-change-the-case-for-investing-in-cra-int
CRA International recently reported stronger-than-expected Q2 2026 sales and EPS and appointed Patrick Hillan as a Vice President in its Life Sciences Practice. This development, combined with rising demand for regulatory and antitrust advisory work, could influence the investment narrative for CRAI. The company's analyst storyline forecasts significant revenue and earnings growth by 2029, with a potential 54% upside to its current price according to one fair value estimate.

Charles River Associates (CRA) Adds Harvard Business School Professor as Academic Affiliate to Antitrust & Competition Economics Practice

https://www.financialcontent.com/article/bizwire-2026-10-1-charles-river-associates-cra-adds-harvard-business-school-professor-as-academic-affiliate-to-antitrust-and-competition-economics-practice
Charles River Associates (CRA) has announced the addition of Professor Feng Zhu, a Harvard Business School professor, as an Academic Affiliate to its Antitrust & Competition Economics Practice. Professor Zhu is an expert in digital transformation, competitive strategy, and business model innovation, with a focus on technology-driven firms and digital markets. His expertise will enhance CRA's offerings, particularly in advising clients on complex issues related to tech companies and antitrust matters, including in China.

CRA International stock reports 12.80 percent Q2 revenue growth

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cra-international-stock-reports-12-80-percent-q2-revenue-growth/70207311
CRA International (CRAI) reported a 12.80% increase in Q2 2026 revenue, reaching USD 210.82 million, exceeding analyst consensus. The consulting firm's adjusted EPS also surpassed expectations at USD 2.16. Demand for specialized advice, partly driven by artificial intelligence, and strong legal and regulatory consulting (80% of revenue) are key growth drivers, with talent acquisition being the main operational challenge.

Charles River Associates adds VP to life sciences unit By Investing.com

https://ca.investing.com/news/stock-market-news/charles-river-associates-adds-vp-to-life-sciences-unit-93CH-4857981
Charles River Associates (CRAI) announced the appointment of Patrick Hillan as Vice President in its Life Sciences Practice. Hillan, previously a partner at another life sciences consulting firm, will focus on medical affairs strategy for pharmaceutical and biotechnology clients. He brings expertise in healthcare professional and patient insight generation, strategic planning, and evidence generation across various therapeutic areas.

A former consulting partner joins Charles River Associates to advise drug and biotech companies

https://www.stocktitan.net/news/CRAI/charles-river-associates-cra-names-patrick-hillan-vice-president-3tmvi63m2ohq.html
Charles River Associates (CRAI) has appointed Patrick Hillan as Vice President in its Life Sciences Practice. Hillan brings extensive experience in medical affairs strategy, having previously advised pharmaceutical and biotechnology companies. His role will involve enhancing CRA's life sciences advisory services and supporting clients with product launches and innovation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement